FDA panel recommends approval of a blood test for colon cancer
NBC News -

Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health’s blood test to detect a cancer that begins in the colon or rectum. The panel voted seven-to-two in favor of benefits outweighing risks when using the test called Shield for colorectal cancer. If approved, Shield could become the second blood-based test for colon cancer diagnosis in the United States after Epigenomics’ Epi proColon, which was approved by in 2016. Colon or rectal cancer...

In related news